3654 results for «372»
3654 results
From repair to replacement: a portfolio of options for your mitral and tricuspid regurgitation patients
16 Nov 2025 – From PCR London Valves 2025
This session explores a full spectrum of therapeutic options for mitral and tricuspid regurgitation, focusing on the PASCAL Precision system for targeted repair and the SAPIEN M3 transcatheter mitral valve replacement. Through beating heart simulators, case discussions, and clinical evidence, participants will understand the versatility and...
Getting the full potential of the supra-annular valve in a changing landscape
16 Nov 2025 – From PCR London Valves 2025
This session explores the evolving landscape of transcatheter aortic valve implantation (TAVI) with a focus on supra-annular valve technology. It covers techniques for achieving commissural alignment, considerations for small aortic annuli, and advantages in treating bicuspid aortic valve disease, supported by clinical data and illustrative cases.
Meet with Myval THV series with real-world case-based learning
17 Nov 2025 – From PCR London Valves 2025
Discover the latest insights from the Myval THV series in this session from PCR London Valves 2025. Through real-world, case-based learning, the session explores lifetime management strategies for TAVI patients, the clinical relevance of intermediate and extra-large valve sizing, and the impact of foreshortening on accurate...
Mitral regurgitation: from guidelines to clinical practice
16 Nov 2025 – From PCR London Valves 2025
This LIVE case symposium brings mitral regurgitation guidelines into real clinical practice. Through step-by-step patient demonstrations and insightful discussion, the session explores how recommendations guide decision-making in ventricular and atrial secondary MR, how the heart team tailors therapy to individual anatomy and comorbidities, and how device iterations...
Myval THV series - Optimise patient outcomes with novel design, data and daily clinical practice
17 Nov 2025 – From PCR London Valves 2025
Discover the essential takeaways from the Myval THV series for improving TAVI outcomes. Learn from high-volume operators how pre-procedural planning, imaging, and sizing rationale guide optimal patient management. See step-by-step implantation of the next-gen Myval Octapro+, including the OctaAlign technique, and understand how precise deployment and...
Open design, confident delivery - How a novel LAA closure device provides predictable outcomes in complex anatomical settings
16 Nov 2025 – From PCR London Valves 2025
This session highlights a novel left atrial appendage (LAA) closure device featuring an open-cage design that delivers predictable clinical and procedural outcomes. It discusses the device's advantages in managing complex anatomical variations and presents implantation techniques across diverse anatomies to improve safety and efficacy.
Planning a lifetime of care in younger patients with Evolut FX+: from index valve to future options
17 Nov 2025 – From PCR London Valves 2025
Watch this PCR London Valves 2025 session to take a deep look at the latest evidence in low-risk aortic stenosis, the durability of contemporary valves, and how anatomy — especially in women and patients with small annuli — shapes long-term strategy.
From index TAVI with Evolut FX+...
PCR London Valves 2025 Welcome Ceremony
16 Nov 2025 – From PCR London Valves 2025
The PCR London Valves 2025 Welcome Ceremony marks the commencement of the conference, setting the stage for an immersive exploration of the latest advances and innovations in valvular heart disease management with a focus on transcatheter interventions.
Coronary sinus reducer for microvascular angina
28 Feb 2020
A 61-year-old man with a history of 2-vessel coronary artery stenting, hypertension and type-2 diabetes mellitus was admitted 5 times within September 2017 and November 2018 for recurrent angina CCS class III-IV refractory to therapy with nitrates, b-blockers and ranolazine in maximally tolerated doses...
OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease
04 Nov 2021
Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.
Author
Concomitant left atrial appendage occlusion and transcatheter aortic valve replacement among patients with atrial fibrillation – The WATCH-TAVR Trial
26 Oct 2023
Panos Xaplanteris provides his take on WATCH-TAVR results which were presented by Samir R. Kapadia at TCT Congress 2023.
Safety and Efficacy of Left Atrial Appendage Occlusion at the Time of Transcatheter Aortic Valve Replacement - The WATCH TAVR Trial
Author
The FLAVOUR Randomized Clinical Trial: Comparison of Fractional Flow Reserve-guided and Intravascular Ultrasound-guided Percutaneous Coronary Intervention in Intermediate Coronary Artery Stenosis
22 Mar 2022
Daniele Giacoppo analyses the main results of the FLAVOUR trial which were presented by Bon-Kwon Koo, from Seoul National University Hospital, South Korea at the American College of Cardiology 2022.
Author
Five-year outcomes of the randomised trial of fractional flow reserve guided PCI compared to coronary artery bypass grafting: FAME 3
02 Apr 2025
Kalaivani Mahadevan provides her take on the five-year outcomes of the FAME 3 trial presented by William F. Fearon at ACC.25 in Chicago.
Author
Harmonising optimal strategy for treatment of coronary artery diseases – bleeding risk: HOST-BR
29 Mar 2025
Daniele Giacoppo and Nicola Ammirabile provide their take on the main results of the HOST-BR trial, presented by Hyo-Soo Kim at ACC.25 in Chicago.
Author
Author
